CASE TX/4-32366A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BAENTELI ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/02710

FILED: 14 MARCH 2003

U.S. APPLICATION NO: 10/507,060 35 USC §371 DATE: 13 JUNE 2005

FOR: 2,4-DIAMINOPYRIMIDINE DERIVATIVES

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the Applicant(s) addresses and Title. Please issue a corrected filing receipt listing the Applicant(s) addresses and Title as follows:

--Applicant(s)

Toshiyuki Honda, Ibaraki Pref., JAPAN Naoko Matsuura, Ibaraki Pref., JAPAN Kazuhiko Nonomura, Ibaraki Pref., JAPAN Osamu Ohmori, Ibaraki Pref., JAPAN Ichiro Umemura, Ibaraki Pref., JAPAN

Title

2,4-Diaminopyrimidine Derivatives--

A copy of the filing receipt with the correction noted is enclosed. Also enclosed is a copy of the first page of the International Search Report showing wherein the text of the title was changed to the above-listed title by the European Patent Office.

No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7909

Date: January 6, 2006 Attorney for Applicants Reg. No. 31,661 Thomas R. Savitsky



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Virginia 22313-1450

FILING OR 371 DRAWINGS TOT CLMS IND CLMS APPL NO. **ART UNIT** FIL FEE REC'D ATTY.DOCKET NO (c) DATE 3 TX/4-32366A

1050 06/13/2005 2183 10/507,060

CONFIRMATION NO. 8326

Date Mailed: 12/08/2005

OC000000017580708*

001095 **NOVARTIS** CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 **EAST HANOVER, NJ 07936-1080**

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE. NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the

USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Rolf Baenteli, Basel, SWITZERLAND; Gerhard Zenke, Rheinfelden, GERMANY; Nigel Graham Cooke, Oberwil, SWITZERLAND; Rudolf Duthaler, Bettingen, SWITZERLAND; Gebhard Thoma, Lorrach, GERMANY; Anette Von Matt, Biel-Benken, SWITZERLAND; Toshiyuki Honda, Ibaraki JAPAN: Pref. Naoko Matsuura, Ibaraki, JAPAN; Pref. Kazuhiko Nonomura, Ibaraki/JAPAN Pref. Osamu Ohmori, Ibaraki, JAPAN, Poul. Ichiro Umernura, Ibaraki, JAPAN, PALL Klaus Hinterding, Wittlingen, GERMANY; Christos Papageorgiou, Riedisheim, FRANCE;



Power of Attorney: The patent practitioners associated with Customer Number 1095.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/02710 03/14/2003

Foreign Applications

UNITED KINGDOM 02062156 03/15/2002

Projected Publication Date: 03/16/2006

Non-Publication Request: No

Early Publication Request: No

Title 2,4-Diaminopyrimidine Derivatives

-Pyrimidine-derivaties

Preliminary Class

712

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where

the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 4-32366A	(Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/EP 03/02710	14/03/2003	15/03/2002
Applicant	·	
NOVARTIS AG		
This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.		
This International Search Report consists of a total of sheets. [X] It is also accompanied by a copy of each prior art document cited in this report.		
Basis of the report		
 With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. 		
the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).		
b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form.		
	ernational application in computer readable for	m.
	this Authority in written form.	
furnished subsequently to	this Authority in computer readble form.	
the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.		
the statement that the info furnished	ormation recorded in computer readable form is	s identical to the written sequence listing has been
2. X Certain claims were fou	nd unsearchable (See Box I).	*
3. Unity of invention is lac	· · · · · · · · · · · · · · · · · · ·	
4. With regard to the title,		
the text is approved as su	bmitted by the applicant.	
X the text has been establis	hed by this Authority to read as follows:	
2,4-DIAMINOPYRIMIDINE	DERIVATIVES	
5. With regard to the abstract.	: .	
TYT)	shmitted by the applicant	
the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.		
6. The figure of the drawings to be publ	ished with the abstract is Figure No.	
as suggested by the appli	icant.	X None of the figures.
because the applicant fail	ed to suggest a figure.	
because this figure better	characterizes the invention.	